Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial

Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial

rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo are WHO-prequalified vaccination regimens against Ebola virus disease (EVD). Challenges associated with measuring long-term clinical protection warrant the evaluation of immune response kinetics after vaccination. Data from a large phase 2 randomized doubl...

Full description

Saved in:
Bibliographic Details
Main Authors: Simon Valayer, Marie Alexandre, Mélanie Prague, Abdoul Habib Beavogui, Seydou Doumbia, Mark Kieh, Brian Greenwood, Bailah Leigh, Marie Poupelin, Christine Schwimmer, Samba O. Sow, Irina Maljkovic Berry, Jens H. Kuhn, Daniela Fusco, Natasha Dubois Cauwelaert, Deborah Watson-Jones, Rodolphe Thiébaut, Yves Lévy, Yazdan Yazdanpanah, Laura Richert, Edouard Lhomme
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Emerging Microbes and Infections
Subjects:
Ebola virus disease
vaccine
immunogenicity
antibody
Western Africa
modelling
Online Access:https://www.tandfonline.com/doi/10.1080/22221751.2024.2432353
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.tandfonline.com/doi/10.1080/22221751.2024.2432353

Similar Items